Author: Ken Dropiewski

MyoKardia Reports Third Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended September 30, 2018. “MyoKardia continues to make encouraging progress toward our mission of changing the […]

First Patient in Hong Kong Treated with Cardiovascular Systems, Inc. Coronary Orbital Atherectomy System

ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient in Hong Kong has been treated with its Diamondback 360® Coronary Orbital Atherectomy System (OAS). This procedure […]

HeartSciences Showcases MyoVista® Wavelet ECG at 2018 Scientific Sessions of the American Heart Association (AHA)

SOUTHLAKE, Texas–(BUSINESS WIRE)–HeartSciences, a medical device company developing next generation ECG devices using continuous wavelet transform (CWT) signal processing, is proud to announce its participation as an exhibitor at the upcoming 2018 Scientific Sessions of the American Heart Association (AHA). The AHA Congress will take place November 10-12, 2018 at […]

Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call

LAVAL, Quebec, Nov. 07, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST) (the “Company” or “Acasti”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will host […]

MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced today announced that Jake Bauer, Chief Business Officer, will provide a corporate update at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November […]

Proteon Therapeutics Announces Third Quarter 2018 Financial Results

WALTHAM, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) — Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended September 30, 2018, and recent business highlights. “We made excellent progress in […]

Correvio Reports Third Quarter 2018 Financial Results

VANCOUVER, Nov. 6, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV /TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today reported financial results for its third quarter ended September 30, 2018 and commented on recent accomplishments and plans. “The past few months at Correvio have been highlighted by meaningful progress across a number of […]

BD Announces Clinical Trial Data for the LUTONIX® 014 Drug-Coated Balloon Below-The-Knee IDE Trial

FRANKLIN LAKES, N.J., Nov. 7, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the safety and efficacy data from the LUTONIX® Drug-Coated Balloon (DCB) IDE, level 1 clinical trial for a below-the-knee (BTK) indication. The clinical study is a prospective, global, multicenter, randomized, controlled trial comparing the […]

XableCath Catheters Demonstrate Ability to Cross Chronic Venous Occlusions

SALT LAKE CITY–(BUSINESS WIRE)–XableCath, a commercial-stage medical device company, announced today that it has demonstrated initial safety and efficacy of its unique catheters for use with chronic venous occlusions, commonly characterized by recalcitrant lesions that have historically proven difficult to cross with standard catheter technologies. XableCath catheters are FDA-cleared for […]